UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022024
Receipt number R000025380
Scientific Title Exploratory study about the effect of silodosin on female voiding dysfunction
Date of disclosure of the study information 2016/04/21
Last modified on 2016/04/21 23:38:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Exploratory study about the effect of silodosin on female voiding dysfunction

Acronym

Exploratory study about the effect of silodosin on female voiding dysfunction

Scientific Title

Exploratory study about the effect of silodosin on female voiding dysfunction

Scientific Title:Acronym

Exploratory study about the effect of silodosin on female voiding dysfunction

Region

Japan


Condition

Condition

Voiding dysfunction

Classification by specialty

Neurology Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study is intended to evaluate the efficacy, safety, and quality of life of Silodosin 4 or 8 mg in a 3-month administration for treatment of voiding dysfunction in patients with neurogenic bladder.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Score based on I-PSS

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Dose comparison

Stratification


Dynamic allocation

YES

Institution consideration


Blocking


Concealment

Pseudo-randomization


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Study drug group (Odd-numbered group):
A 12-week administration of Silodosin 2 mg twice daily

Interventions/Control_2

Study drug group(Even-numbered group):
A 8-week administration of Silodosin 4 mg twice daily after a 4-week administration of Silodosin 2 mg twice daily

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >

Gender

Female

Key inclusion criteria

1)over 50ml residual urine volume
or
2)over 2 points I-PSS
and
3)patinets who can answer the questionnaire
4)out-patient
5)Patients who agree to contraception use

Key exclusion criteria

1)severe heart disease
2)severe liver diseae or over 3mg/dl total bilirubin or over 2.5 times AST(GOT)o ALT(GPT)
3)severe kidney disease or over 1.5mg/dl creatinine
4)severe hypotention
5)women who are pregnant, breast-feeding, or seeking to conceive or may conceive due to improper contraception method during the study period
6)Patients receiving surgical therapy, which may influence the lower urinary tract function
7)Patients receiving nonpharmacologic therapy within 4 weeks prior to the study commencement, which may influence the lower urinary tract function
8)Patients who received an investigational drug in other clinical study within 1 month prior to the study commencement (the period of which should be calculated based on the date on which the investigational drug was administered)
9)Patients who are otherwise ineligible to take part in the study as judged by Principal Investigator or other relevant person

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoyuki Uchiyama

Organization

Dokkyo Medical University

Division name

Neurourology and Continence Center

Zip code


Address

880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi

TEL

0282-86-1111

Email

t-uchi@dokkyomed.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tomoyuki Uchiyama

Organization

Dokkyo Medical University

Division name

Neurourology and Continence Center

Zip code


Address

880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi

TEL

0282-86-1111

Homepage URL


Email

t-uchi@dokkyomed.ac.jp


Sponsor or person

Institute

Dokkyo Medical University

Institute

Department

Personal name



Funding Source

Organization

self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 04 Month 21 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2008 Year 11 Month 25 Day

Date of IRB


Anticipated trial start date

2009 Year 01 Month 05 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 04 Month 21 Day

Last modified on

2016 Year 04 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025380


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name